Double-Target attack: new cell therapy trial aims to tame tough melanoma
NCT ID NCT07193966
Summary
This study is testing a new type of personalized cell therapy called CAR-T that is engineered to attack melanoma cancer cells using two targets, NG2 and DLL3. It is for adults whose melanoma has come back or stopped responding to standard treatments. The main goals are to see if the treatment is safe and if it can shrink tumors and help patients live longer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shenzhen Geno-immune Medical Institute
RECRUITINGShenzhen, Guangdong, 518000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.